Johnson & Johnson Provides Upbeat Booster Shot Update

The security boasts reasonably priced options at the moment

Deputy Editor
Sep 21, 2021 at 10:28 AM
facebook twitter linkedin

The shares of Johnson & Johnson (NYSE:JNJ) are up 0.7% to trade at $164.90 at last check, after the company said a second shot of its Covid-19 vaccine administered about two months after the first dose increases effectiveness against moderate to severe disease to 94%. Plus, the pharmaceutical concern added the booster shot increases antibody levels four to six times.

On the charts, Johnson & Johnson stock yesterday fell to a three-month low of $162.16, with pressure coming from the once-supportive 150-day moving average, which coincides with a recent ceiling that has formed at the $166 level. Year-over-year, though, the security is still up 14%.

An unwinding of pessimism in the options could boost the shares. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), JNJ's 10-day put/call volume ratio stands higher than 80% of readings in the past year. This means puts have been getting picked up at a quicker-than-usual clip in the last two weeks.

At the moment, JNJ options are reasonably priced. This is per Johnson & Johnson stock's  Schaeffer's Volatility Index (SVI) of 19%, which ranks in the 30th percentile of its annual range, implying that options players are pricing in relatively low volatility expectations.



Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!